Skip to content
Catalyst

PapersPMID:40077714

Clinical Evaluation of Ganoderma lucidum Spore Oil for Triglyceride Reduction: A Randomized, Double-Blind, Crossover Study.

Nutrients2025The record ↗

findings
7
compound
1
endpoints
7
PMID:40077714
  1. Finding, moderate evidencelowersAspartate aminotransferase
  2. Finding, moderate evidencelowersSerum alkaline phosphatase
  3. Finding, moderate evidencelowersLDL cholesterol
  4. Finding, moderate evidencelowersTriglycerides
  5. Finding, moderate evidencelowersTotal cholesterol (TC)
  6. Finding, moderate evidenceraisesHDL cholesterol
  7. Finding, moderate evidencelowersAlanine aminotransferase
Study, every finding
RCT · 3 months
Dose studied, every finding
3 softgel capsules twice daily, 0.5 g extract per softgel, approximately 3.0 g/day
Population, every finding
Adults aged 18 to 65 years with triglycerides of 1.70 to 2.25 mmol/L; 55 per arm analysed

What moved

How to read these marks →
  • “As shown in Table 3, among the safety parameters, the intervention group exhibited significantly lower levels of ALP (74.94 ± 12.68 U/L), TBA (3.20 ± 1.47 µmol/L), AST (21.00 ± 5.37 U/L), ALT (20.94 ± 6.52 U/L), GGT (23.19 ± 14.60 U/L), direct bilirubin (3.43 ± 1.12 µmol/L), and total bilirubin (13.00 ± 4.10 µmol/L) compared to the placebo group (ALP: 85.20 ± 24.57 U/L, TBA: 3.95 ± 1.92 µmol/L, AST: 24.17 ± 6.04 U/L, ALT: 33.13 ± 24.80 U/L, GGT: 4.20 ± 1.14 µmol/L, direct bilirubin: 25.69 ± 11.81 µmol/L, total bilirubin: 15.83 ± 5.35 µmol/L; p < 0.05).”
  • “As shown in Table 2, after 12 weeks of treatment, the intervention group exhibited significantly lower levels of TG (1.51 ± 0.55 mmol/L), LDL-C (2.68 ± 0.67 mmol/L), and TC (4.87 ± 0.89 mmol/L) compared to the placebo group (TG: 1.88 ± 0.16 mmol/L, LDL-C: 3.20 ± 0.97 mmol/L, TC: 5.25 ± 0.91 mmol/L; p < 0.05).”
  • Increases HDL cholesterol

    moderate

    “Conversely, HDL-C levels were significantly higher in the intervention group (1.51 ± 0.22 mmol/L) than in the placebo group (1.36 ± 0.30 mmol/L; p < 0.05).”

Study record

Design
randomised controlled trial
Species
human
Population
Adults aged 18 to 65 years with borderline-high triglycerides (TG 1.70 to 2.25 mmol/L) in China; Ganoderma lucidum spore oil (GLSO) softgel extract (a spore oil product, not whole fruiting body)
Participants
113
Comparator
placebo
Duration
84 days
Endpoints measured
30